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Abstract
Background: Neutrophil to lymphocyte ratio (NLR) was introduced to predict poor prognosis in various diseases,
but not all variants of ANCA-associated vasculitis (AAV). In this study, we aimed to investigate whether NLR at
diagnosis can estimate vasculitis activity at diagnosis and poor prognosis during follow-up in patients with AAV.
Methods: We retrospectively reviewed the medical records of 160 patients with AAV. We collected clinical and
laboratory data at diagnosis and obtained remission and death as poor prognosis. We stratified AAV patients into
three groups according to tertile and defined the lower limit of each highest tertile as the optimal cut-off (5.9 for
NLR and 15.0 of Birmingham vasculitis activity score [BVAS] for severe AAV).
Results: The mean age at diagnosis was 55.2 years and 48 patients were men. In the univariable linear regression
analysis, BVAS was negatively correlated with lymphocyte count and positively correlated with erythrocyte sedimentation
rate (ESR), C-reactive protein (CRP) and NLR. In the multivariable linear regression analyses of ESR and CRP with either
lymphocyte count or NLR, lymphocyte count (β = − 0.160) and NLR (β = 0.169) were associated with BVAS. Patients
having NLR≥ 5.9 exhibited severe AAV more frequently than those having NLR < 5.9 at diagnosis (relative 2.189, P = 0.
023). Patients having NLR≥ 5.9 exhibited a higher frequency of AAV relapse, but not death, than those having NLR < 5.9
(P = 0.016).
Conclusions: NLR at diagnosis can estimate vasculitis activity at diagnosis and predict relapse during follow-up in
patients with AAV.
Keywords: Antineutrophil cytoplasmic antibody-associated vasculitis, Neutrophil to lymphocyte ratio, Vasculitis activity,
Prognosis
Background
Antineutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) is a group of three systemic vasculitides
involving small vessels from capillaries to intraparenchy-
mal arterioles and venules: microscopic polyangiitis
(MPA), granulomatosis with polyangiitis (GPA) and eo-
sinophilic granulomatosis with polyangiitis (EGPA) [1].
MPA and GPA exhibit similar clinical manifestations of
pulmonary, renal and ear-nose-throat manifestations, des-
pite differences in genetic backgrounds, aetiologies,
ANCA type, and histologic findings [1–3], whereas, EGPA
shows both necrotising vasculitis and allergic components
such as asthma and eosinophilia [1, 2, 4].
Neutrophil to lymphocyte ratio (NLR) has been recently
introduced and widely used to predict poor prognosis in
several cancers and inflammatory diseases [5, 6]. Neutrophil
count may be often directly proportional to the inflamma-
tory burdens, furthermore, activated neutrophils are very
closely associated with the pathogenesis of AAV. By con-
trast, lymphocyte count may decrease in autoimmune in-
flammatory diseases [7]. Particularly, lymphopenia with low
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numbers of CD4+ T cells can be observed in GPA due to
an extensive recruitment of peripheral T cells to the af-
fected tissues [8]. Therefore, it can be reasonably speculated
that NLR may reflect the inflammatory burdens in patients
with systemic vasculitis. So far, NLR has been reported to
be associated with disease activity and prognosis in
Takayasu arteritis, Behcet disease, Kawasaki vasculitis and
Henoch Schonlein purpura [9–11]. However, there were
only a few reports the clinical role of NLR in patients with
AAV [12, 13]. Furthermore, there was no study to demon-
strate the association of NLR with both vasculitis activity
and poor prognosis including relapse and death in a consid-
erable number of patients with MPA, GPA and EGPA to
date. Hence, in this study, we aimed to investigate whether
NLR at diagnosis can estimate vasculitis activity at diagno-
sis and poor prognosis during follow-up in 160 patients
with AAV, who were not administered immunosuppressive
drugs before AAV diagnosis.
Methods
Patients
We retrospectively reviewed the medical records of 160
patients with AAV according the inclusion criteria as fol-
lows: i) patients who were first classified as AAV from
October 2000 to September 2017 at the Department of
Internal Medicine, Yonsei University College of Medi-
cine, Severance Hospital, where this study was con-
ducted as a monocentric investigation; ii) patients who
fulfilled the American College of Rheumatology 1990
criteria for the classification for AAV and then reclassi-
fied by the 2007 European Medicines Agency algorithm
modified by the 2012 revised Chapel Hill Consensus
Conferences Nomenclature of Vasculitis [1–4]; iii) pa-
tients who had well-documented medical records with
which to calculate items of Birmingham vasculitis activ-
ity score (BVAS) and five factor score (FFS (2009)) at
diagnosis [14–16]; iv) patients who had results on peri-
nuclear (P)-ANCA and cytoplasmic (C)-ANCA or mye-
loperoxidase (MPO)-ANCA and proteinase 3 (PR3)-
ANCA at diagnosis [17]; v) patients who had no con-
comitant or previous medical conditions to disturb AAV
classification, which was confirmed by the 10th revised
International Classification of Diseases [18]; and vi) pa-
tients who received no immunosuppressive drugs prior
to diagnosis of AAV, which was searched by the Korean
Drug Utilization Review system. This study was ap-
proved by the Institutional Review Board of Severance
Hospital (4–2017-0673), who waived the need for
patient written informed consent, as this was a retro-
spective study.
Clinical data
We obtained age and gender as demographic data at the
time of the first diagnosis of AAV and searched the initial
ANCAs. When an AAV patient exhibited an item de-
scribed in BVAS, we considered him or her to have an
organ-specific involvement of AAV, regardless of tissue bi-
opsy findings as below: general manifestation including
muscle pain, joint symptoms, fever and weight loss ≥2 kg;
cutaneous manifestation including skin rashes and ulcera-
tions; mucous membrane / eyes manifestation including
oral or genital ulceration, inflammation in sclera or con-
junctiva, impairment in visual function, uveitis and retin-
itis; ear nose throat manifestation including inflammation
in nasal passage or paranasal sinus and hearing loss; chest
manifestation including inflammation in both lung paren-
chyma and pleura; cardiovascular manifestation including
coronary arterial occlusion, heart failure and pericarditis;
abdominal manifestation including gastrointestinal bleed-
ing and mesenteric arterial occlusion; renal manifestation
including proteinuria > 1+ on urine stick, haematuria ≥10
RBCs/HPF and renal dysfunction; nervous system mani-
festation including central and peripheral neuropathies.
We also calculated the total score of BVAS and FFS
(2009) at diagnosis.
Laboratory data
We collected laboratory results at diagnosis, which rep-
resent the inflammatory burdens in the real clinical set-
tings including complete blood counts [white blood cell
(WBC), neutrophil, lymphocyte, and platelet counts];
erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) before the administration of immunosup-
pressive drugs to AAV patients. The follow-up duration
was defined as the duration from diagnosis to the last
visit in patients without relapse, whereas it was defined
as the time from diagnosis to the first relapse in patients
with relapse. Therefore, the follow-up duration in this
study meant the relapse free period of AAV.
Prognosis
Remission was determined as no active disease requiring
the maintenance therapy, relapse was defined as active
disease after remission [19]. We also counted all cause
death in AAV patients.
Equations of NLR and optimal cut-off
NLR was calculated as a ratio of neutrophil count over
lymphocyte count at diagnosis [NLR = neutrophil count
(/uL) / lymphocyte count (/uL)] [9, 10]. We stratified
AAV patients into three groups according to tertile and
define the lower limit of each highest tertile as the opti-
mal cut-off [6]. The optimal cut-offs were set at 15.0 for
severe AAV based on BVAS and 5.9 for NLR. In particu-
lar, in this study, we discretionally define severe AAV
when BVAS is 15.0 or greater.
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Statistical analyses
We expressed continuous variables as a mean ± standard
deviation, and categorical variables as number (%). We
assessed the standardised correlation coefficient by the
multivariable linear regression analysis using variables
with significance in the univariable analysis. We com-
pared categorical variables between the two groups, and
analysed the relative risk (RR) using the chi square and
Fisher’s exact tests. Also we compared cumulative re-
lapse free and patient survivals between the two groups
using the Kaplan-Meier survival analysis. We conducted
all statistical analyses using SPSS software (version 23
for windows; IBM Corp., Armonk, NY, USA). P-values <
0.05 were considered statistically significant.
Results
Baseline characteristics of 160 patients with AAV
The baseline characteristics are described in Table 1.
Eight-five of 160 patients (53.1%) were classified as
MPA, 41 patients (25.6%) as GPA and 34 patients
(21.3%) as EGPA. The mean age at diagnosis was
55.2 years and 48 patients (30.0%) were men.
Ninety-nine patients (61.9%) and 27 patients (16.9%)
had MPO-ANCA (or P-ANCA) and PR3-ANCA (or
C-ANCA), respectively. Seven patients (4.4%) had
MPO-ANCA (or P-ANCA) as well as PR3-ANCA (or
C-ANCA), and 41 patients (25.6%) had no ANCA. The
most common clinical manifestation of AAV at diagno-
sis was renal manifestation (59.4%), followed by chest
(52.5%) and general (44.4%) manifestations. The mean
BVAS at diagnosis was 11.9 and the mean FFS (2009) at
diagnosis was 1.3. In terms of laboratory results related
to the inflammatory burdens at diagnosis, the mean
WBC, neutrophil, lymphocyte and platelet counts were
10,175.6/mm3, 7227.5/mm3, 1564.0/mm3 and 327,500.
0/mm3, respectively. The mean NLR was 6.6. The mean
follow-up duration was 55.6 months. During the
follow-up of more than 12 weeks, 43 patients (26.9%)
exhibited relapse after remission and 14 patients (8.8%)
died.
Univariable and multivariable linear regression analyses
In the univariable linear regression analysis, BVAS was
negatively correlated with lymphocyte count (r = −
0.198, P = 0.012) and positively correlated with ESR (r
= 0.218, P = 0.006) and CRP (r = 0.169, P = 0.033). BVAS
was also significantly correlated with NLR (r = 0.204, P
= 0.009) (Table 2). We performed the multivariable lin-
ear regression analyses of ESR and CRP with either
lymphocyte count or NLR. In terms of multivariable
linear regression analysis of lymphocyte, ESR and CRP,
only lymphocyte count was significantly associated with
BVAS (β = − 0.160, 95% confidence interval [CI] -0.003,
0.000, P = 0.045). In terms of multivariable linear
Table 1 Baseline characteristics of 160 patients with AAV
Variables Values
Variants of AAV
MPA 85 (53.1)
GPA 41 (25.6)
EGPA 34 (21.3)
Demographic data at diagnosis
Age (year old) 55.2 ± 15.1
Male gender (N, (%)) 48 (30.0)
ANCA at diagnosis (N, (%))
MPO-ANCA (or P-ANCA) 99 (61.9)
PR3-ANCA (or C-ANCA) 27 (16.9)
MPO-ANCA (or P-ANCA) and
PR3-ANCA (or C-ANCA)
7 (4.4)
ANCA negative 41 (25.6)
Clinical manifestations at diagnosis (N, (%))
General 71 (44.4)
Cutaneous 37 (23.1)
Mucous membranes/eyes 12 (7.5)
Ear Nose Throat (ENT) 56 (35.0)
Chest 84 (52.5)
Cardiovascular 45 (28.1)
Abdominal 10 (6.3)
Renal 95 (59.4)
Nervous system 52 (32.5)
Vasculitis activity and prognostic factors at diagnosis
BVAS or BVAS for GPA 11.9 ± 7.6
FFS (2009) 1.3 ± 1.0
Laboratory results at diagnosis
WBC (/mm3) 10,175.6 ± 4758.2
Neutrophil (/mm3) 7227.5 ± 4047.2
Lymphocyte (/mm3) 1564.0 ± 721.2
Platelet (×1,000/mm3) 327.5 ± 141.9
ESR (mm/hr) 60.1 ± 37.4
CRP (mg/L) 43.0 ± 56.5
NLR at diagnosis 6.6 ± 8.3
Prognosis
Follow-up duration (months) 55.6 ± 51.5
Relapse (N, (%)) 43 (26.9)
Death (N, (%)) 14 (8.8)
Values are expressed as mean and standard deviation or N (%)
AAV antineutrophil associated vasculitis, MPA microscopic polyangiitis, GPA
granulomatosis with polyangiitis, EGPA eosinophilic granulomatosis with
polyangiitis, MPO myeloperoxidase, ANCA antineutrophil cytoplasmic antibody,
P-ANCA perinuclear ANCA, PR3 proteinase 3, C-ANCA cytoplasmic ANCA, BVAS
Birmingham vasculitis activity score, FFS five factor score, WBC white blood
cell, ESR erythrocyte sedimentation rate, CRP C-reactive protein, NLR neutrophil
to lymphocyte ratio
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regression analysis of NLR, ESR and CRP (R = 0.279), only
NLR was significantly associated with BVAS (β = 0.169,
95% CI 0.010, 0.299, P = 0.036) (Table 2).
RR of severe AAV based on BVAS
When we classified AAV patients into two groups based
on the cut-off of NLR, patients having NLR ≥ 5.9 exhib-
ited the higher frequency of severe AAV than those hav-
ing NLR < 5.9 (47.2% vs. 29.0%, P = 0.023). Particularly,
patients having NLR ≥ 5.9 had a significantly higher risk
of severe AAV than those not having (RR 2.189, 95% CI
1.107, 4.330) (Fig. 1).
A predictor of relapse and death during follow-up
We evaluated whether the highest tertile of NLR (5.9 or
greater) at diagnosis can predict relapse of AAV and
death during the follow-up using Kaplan-Meier survival
analysis. Cumulative relapse free and patient survival
rates were depicted in Fig. 2. Patients having NLR ≥ 5.9
exhibited the higher frequency of relapse of AAV than
those having NLR < 5.9 (P = 0.016). Thus, NLR has a po-
tential of a predictor of relapse of AAV during the
follow-up. However, there was no significant difference
in cumulative patient survival rate between patients hav-
ing NLR ≥ 5.9 and those NLR < 5.9 at diagnosis.
Discussion
In this study, we investigated whether NLR at diagnosis can
estimate vasculitis activity at diagnosis and poor prognosis
during follow-up in 160 patients with AAV in a single
centre. First, in terms of vasculitis activity of AAV, we
conclude that lymphocyte count and NLR are significantly
correlated with BVAS, comparable to ESR and CRP. Mean-
while, among four variables, lymphocyte count and NLR
are significantly associated with BVAS. The statistical sig-
nificance of the association between BVAS and NLR was
slightly higher than that between BVAS and lymphocyte
count (β = 0.169 vs. β = − 0.160). In addition, NLR ≥ 5.9 (RR
2.189) can estimate severe AAV based on BVAS. Second, in
terms of prognosis of AAV, we conclude that NLR ≥ 5.9 at
diagnosis is a predictor of relapse of AAV, but not death,
during follow-up. Therefore, we believe that NLR at diag-
nosis is a useful marker to estimate vasculitis activity at
diagnosis and poor prognosis during follow-up in AAV
patients.
In addition to NLR, lymphocyte count also exhibited a
significant correlation and association with BVAS along
with ESR and CRP. Unlike NLR, lymphocyte count is auto-
matically counted and reported, suggesting that lymphocyte
count is much more convenient than NLR. Nonetheless,
NLR has been widely proposed to estimate the inflamma-
tory burdens and predict prognosis than lymphocyte count
in various diseaes. NLR includes two different lineages of
immune cells, neutrophils and lymphocytes. Neutrophils
are mainly in charge of nonspecific and early systemic in-
flammation. Neutrophil count may be elevated by infec-
tions or temporarily by glucocorticoid use, whereas it may
be reduced by neutrophil-consuming medical conditions or
immunosuppressive drugs. Meanwhile, lymphocyte partici-
pates in relatively late immune reactions. Lymphocyte
count may also be affected by general health and stress or
various autoimmune diseases. Therefore, NLR, in which
two lineages of immune cells possessing different characters
are integrated, is considered a more reliable and comple-
mentary marker than counts of single immune cells such as
lymphocytes [4, 20].
In this study, we first demonstrated that NLR ≥ 5.9
at diagnosis can predict relapse of AAV during
follow-up. Calculating NLR at diagnosis of AAV im-
plies that they mainly reflect the vasculitis activity of
AAV before the administration of immunosuppressive
drugs. In our previous studies, we demonstrated that
BVAS at diagnosis representing the initial inflam-
matory burdens could predict poor prognosis such as
relapse or refractory disease in patients with AAV
[21, 22]. Therefore, the clinical role of NLR at diag-
nosis to predict relapse of AAV can be explained by
the positive link between NLR and BVAS. With these
results, we suggest that physicians may calculate NLR
at diagnosis to predict poor prognosis of AAV during
follow-up. Furthermore, we also suggest that the more
frequent visits, laboratory tests and evaluation of
treatment efficacy may be necessary in AAV patients
having NLR ≥ 5.9.
The number of neutrophils can be increased by the use
of glucocorticoids, whereas it can be decreased by the use
of immunosuppressive drugs by bone marrow suppres-
sion. Therefore, we included only patients who had nei-
ther glucocorticoid nor immunosuppressive drugs in this
study. In addition, we excluded 12 patients with ischaemic
heart disease or peripheral vascular diseases, as NLR
Fig. 1 Relative risk of severe AAV based on BVAS. Patients having NLR≥
5.9 exhibited the higher frequency of severe AAV than those having
NLR < 5.9 (47.2% vs. 29.0%, RR 2.189, P= 0.023). AAV; ANCA-associated
vasculitis: ANCA: antineutrophil cytoplasmic antibody; BVAS: Birmingham
vasculitis activity score; NLR: neutrophil to lymphocyte ratio
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might be influenced by atherosclerosis or peripheral vas-
cular diseases [23, 24].
Our study has two advantages. First, we demonstrated
the clinical roles of NLR at diagnosis to not only esti-
mate vasculitis activity at diagnosis, but also predict re-
lapse during follow-up in patients with all variants of
AAV. Second, we could control the clinical and labo-
ratory confounding factors including inter-observer or
inter-centric variation due to a single-centric study.
However, this study also has several limitations. First,
we could not perform the subgroup analysis of clinical
features of patients with NLR ≥ 5.9, but without severe
AAV or relapse due to the retrospective study-design.
Second, the number of AAV patients in this study was
not large enough to represent the ethnic feature of Ko-
rean patients with AAV. If future studies with the larger
number of patients can calculate BVAS and NLR pro-
spectively, they might reveal the reliable and valuable
results of NLR to not only estimate the current BVAS,
but also predict poor prognosis during follow-up.
Conclusions
NLR at diagnosis can estimate vasculitis activity at diag-
nosis and predict relapse during the follow-up in pa-
tients with AAV. Thus, we suggest that physicians
should pay more attention to patients with NRL at diag-
nosis ≥5.9, encourage them to visit more often and pro-
long the period of maintenance therapy even in those
achieving remission.
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